In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.

Join Dr. Culton as she discusses the unmet treatment needs in bullous pemphigoid, and the importance of understanding pathophysiology in disease management.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Dr. Jeff Yu presents the clinical presentation of pediatric AD and highlights how type 2 inflammation contributes to symptoms and development of atopic comorbidities such as food allergy and asthma at PeDRA 2025

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

Dr. Amy Paller describes potential biomarkers of subclinical control at EADV 2025

Listen as Dr. Donna Culton discusses the importance of crosstalk between autoantibodies and type 2 inflammation in the development of bullous pemphigoid.

Join Dr. Jason Hawkes as he explains the importance of type 2 inflammation in chronic spontaneous urticaria.
Dr. Butler delves into the multifaceted biological mechanisms, including type 2 inflammation, that drive chronic pruritus in older adults. He explains how age-related changes contribute to epidermal barrier dysfunction, neuropathic damage, and immune decline, leading to chronic pruritus.

Join Prof. Kathryn Peterson for an expert review on how different immune cells and inflammatory mediators contribute to the pathogenesis of EoE.
This symposium explores the key role type 2 inflammation plays in atopic dermatitis and prurigo nodularis and debunks common misconceptions about these skin diseases with key insights from Drs Ahuva Cices and Naiem Issa.